Loading
HKSEHealthcareBiotechnology
Latest quote
HK$31.22
−HK$1.82 · -5.51%
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
Latest quote
HK$31.22
−HK$1.82 · -5.51%
Regular session · HKT · Market data may be delayed.
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
52-week range
Current HK$31.22
Regular session · HKT · Market data may be delayed.
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
52-week range
Current HK$31.22
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.71B CNY | 706.68M CNY | 125.93M CNY | 12.79M CNY | 54K CNY |
| Cost of goods sold | 524.82M CNY | 177.79M CNY | 34.41M CNY | 4.65M CNY | 23K CNY |
| Gross profit | 1.18B CNY | 528.89M CNY | 91.52M CNY | 8.15M CNY | 31K CNY |
| Research and development | 511.04M CNY | 528.04M CNY | 540.05M CNY | 809.74M CNY | 613.43M CNY |
| Selling, general, and administrative | 1.06B CNY | 758.15M CNY | 396.57M CNY | 603.23M CNY | 440.83M CNY |
| Operating expenses | 1.57B CNY | 1.65B CNY | 1.02B CNY | 264.95M CNY | 1.03B CNY |
| Interest income | 63.6M CNY | 95.21M CNY | 107.67M CNY | 38.48M CNY | 28.88M CNY |
| Interest expense | 22.67M CNY | 22.19M CNY | 23.06M CNY | 5.59M CNY | 4.82M CNY |
| Depreciation and amortization | 132.71M CNY | 110.17M CNY | 76.78M CNY | 42.77M CNY | 31.12M CNY |
| Operating income | −386.24M CNY | −1.12B CNY | −932.74M CNY | −256.8M CNY | −1.03B CNY |
| Net income | −297.77M CNY | −1.04B CNY | −844.46M CNY | −247.28M CNY | −1.01B CNY |
Company facts updated Sep 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
